Is the business good?
How good a business is BCRX?
BioCryst Pharmaceuticals, Inc. keeps −33% of every revenue dollar as operating profit, against 12% for the median Drug Manufacturers - Specialty & Generic name.
−33%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q2 2026
- Share count, year on year
- +21%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 21%
R&D as % of revenue
- Gross margin
- 98%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −981% |
| FY2021 | −113% |
| FY2022 | −55% |
| FY2023 | −31% |
| FY2024 | −0.56% |
| FY2025 | 39% |
Details›
- Gross margin12 months to Q2 2026
- 98%
- Operating margin12 months to Q2 2026
- −33%
- Net margin12 months to Q2 2026
- −41%
- Free cash flow margin
- 40%
- R&D as % of revenue
- 21%
- Revenue, trailing twelve months
- $941M
- Free cash flow, trailing twelve months
- $373M
- Net income, trailing twelve months
- −$385M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #2 of 28 by Smart Score